ORIGINAL RESEARCH

Identification of a Novel Prognostic Classification Model in Epithelial Ovarian Cancer by Cluster Analysis

Kelie Chen,[1,2,]* Yuequn Niu,[3,]*
Shengchao Wang,[1,]* Zhiqin Fu,[4]
Hui Lin,[1,2] Jiaoying Lu,[2]
Xinyi Meng,[2] Bowen Yang,[2]
Honghe Zhang,[1] Yihua Wu,[1,2]
Dajing Xia, [iD][1,2] Weiguo Lu[1]

[1]Department of Gynecologic Oncology,
Women's Hospital, School of Medicine,
Zhejiang University, Hangzhou 310058,
People's Republic of China; [2]Department
of Toxicology, School of Public Health,
School of Medicine, Zhejiang University,
Hangzhou 310058, People's Republic of
China; [3]Department of Thoracic Surgery,
First Affiliated Hospital, School of
Medicine, Zhejiang University, Hangzhou
310003, People's Republic of China;
[4]Department of Gynecological Oncology,
Zhejiang Cancer Hospital, Hangzhou
310022, People's Republic of China

*These authors contributed equally to
this work

Background: Heterogeneity plays an essential role in ovarian cancer. Patients with different clinical features may manifest diverse patterns in diagnosis, treatment, and prognosis. The aim of the present study was to identify a novel ovarian cancer–classification model through cluster analysis and assess its significance in prognosis.
Methods: Among patients diagnosed with ovarian cancer in the Women's Hospital School of Medicine, Zhejiang University between January 2014 and May 2019, 328 patients were included in a *K*-mean cluster analysis and 176 patients followed up. Major clinical indicators, overall survival, and recurrence-free survival in different subgroups were compared.
Results: Two clusters for ovarian cancer were identified and grouped as noninflammatory (n=247) and inflammatory subtypes (n=81). Compared with the noninflammatory subgroup, the inflammatory subgroup presented a statistically significantly higher level of median CRP (median (IQR) 20.4 [7.8–47.3] vs 1.2 [0.4–3.5], $p<0.001$), neutrophil percentage (median (IQR) 76.9 [72.6–81.3] vs 66.2 [61.0–72.0], $p<0.001$), leukocyte count (median (IQR) 8.9 [7.0–10.0] vs 6.0 [5.1–7.2], $p<0.001$), fibrinogen (median (IQR) 5.0 [4.4–6.0] vs 3.4 [2.9–3.9], $p<0.001$), and platelet count (median (IQR) 324 [270–405] vs 229 [181.5–269], $p<0.001$). During a median follow-up of 52 months, 21 participants (16.3%) died in the noninflammatory group, while 14 (29.8%) died in the inflammatory group (HR 2.15, 95% CI 1.09–4.23; $p=0.024$). Death/recurrence was observed in 38 (29.5%) patients from the noninflammatory group and 25 (53.2%) from the inflammatory group (HR 2.32, 95% CI 1.40–3.85; $p<0.001$).
Conclusion: Our study revealed a novel classification model of ovarian cancer that features inflammation. Inflammation predicts shorter survival and poorer prognosis, suggesting the significance of inflammation in the management of ovarian cancer.
Keywords: ovarian cancer, classification, heterogeneity, cluster analysis, inflammation, prognosis

Correspondence: Dajing Xia
Department of Toxicology, School of Public
Health, School of Medicine,
Zhejiang University, 866 Yuhangtang
Road, Hangzhou, Zhejiang 310058,
People's Republic of China
Tel/Fax +86-0571-88208140
Email dxia@zju.edu.cn

Weiguo Lu
Department of Gynecologic Oncology,
Women's Hospital, School of Medicine,
Zhejiang University, 1 Xueshi Road,
Hangzhou 310006, People's
Republic of China
Tel +86-571-8706-1501
Fax +86-571-87061878
Email lbwg@zju.edu.cn

Introduction

Ovarian cancer is the fifth–most frequent cause of cancer death in women and the leading cause of death from gynecological cancer, accounting for 5% of estimated cancer deaths.[1–3] With most patients diagnosed at an advanced stage, the prognosis remains unsatisfactory.[1] In fact, ovarian cancer is a collective term for cancers of the ovaries, peritoneum, and fallopian tube. Ovarian cancer consists of heterogeneous subtypes classified by International Federation of Gynecology and Obstetrics (FIGO) stage, tissue of origin,[4–6] pathological grade,[7] clinical presentation,[8] molecular profiling,[9,10] and treatment.[6,11] These subtypes can vary from each other in

initial symptoms, diagnosis, treatment protocol, and prognosis.[4,5] A practical classification of ovarian cancer is of great significance to differentiate specific subgroups, guide personalized treatment, and ultimately improve prognosis.

Several widely known models have been carried out to categorize ovarian cancers. The revised dualistic model, integrating histopathologic classification with molecular genetic features, classified ovarian cancers into two groups (type I and type II).[7] Type I was further divided into three subtypes. In general, type I tumors usually derived from benign extraovarian lesions, while many type II carcinomas developed from intraepithelial carcinomas in the fallopian tube.[7] Type I cancers were typically indolent, with a good prognosis. In contrast, type II cancers were more aggressive and accompanied worse outcomes.[7] Emphasizing the dramatic differences between the two groups, the dualistic model was expected to guide ovarian cancer screening, prevention, and treatment. Another two studies focusing on genomic and/or proteomic data based on The Cancer Genome Atlas identified different subtypes and cast a new light on the understanding of ovarian cancer.[9,10]

The aforementioned classification models rely on histopathological and molecular features obtained after invasive procedures and operation. More accessible and convenient classification paradigms would be beneficial to have a better understanding of the condition of patients prior to invasive procedures and provide additional information for clinical decision-making. Therefore, the current study aimed to identify preoperative ovarian cancer subtypes through cluster analysis of easily accessible variables, such as demographic data and laboratory results, and to evaluate the feasibility of our novel classification paradigm in the survival prediction of ovarian cancer patients.

Methods
Study Population and Data Collection
This study included patients who had been histopathologically diagnosed with epithelial ovarian cancer at the Women's Hospital School of Medicine, Zhejiang University between January 2014 and May 2019. Exclusion criteria were nonepithelial ovarian tumors, neoadjuvant chemotherapy before interval debulking surgery, suboptimal debulking, borderline tumors, metastatic ovarian cancer, previous surgery for ovarian cancer, recurrent ovarian cancer, history of malignant tumors, and scarce information to carry

out our analysis. Results of laboratory tests taken prior to invasive operations were collected retrospectively from the electronic medical records. Age, BMI, histopathological subtype, FIGO stage, and grade were extracted as well. Patients diagnosed between January 2014 and December 2016 were followed up with telephone or hospital records until January 2020. The outcomes of interest were overall survival and recurrence-free survival. Overall survival was defined as the time between primary diagnosis and death. Recurrence-free survival was defined as the time from primary diagnosis to disease recurrence or progression or death from any cause, whichever occurred first. Disease progression was defined according to Response Evaluation Criteria in Solid Tumors version 1.1 or on the basis of CA125 level elevated from baseline. The present retrospective observational study was approved by the ethical committee of the Women's Hospital School of Medicine, Zhejiang University (decision 20,180,196). Informed consent was waived, due to the retrospective nature of the study and anonymous analyses of the data. All analyses were carried out with confidentiality. This study was performed in compliance with the ethical standards of the Declaration of Helsinki.

Design and Procedures
Variables selected for all participants (Table 1) to enter the cluster analysis were age, BMI, and laboratory results. Histopathological characteristics were compared between groups after clustering. The dualistic model of epithelial ovarian carcinogenesis was adopted to divide tumors into type I and type II.[7] Cluster analysis was validated by verifying its association with overall survival and recurrence-free survival. Patients diagnosed between January 2014 and December 2016 were included in the survival analysis.

Statistical Analysis
Cluster analysis was performed using K-mean cluster analysis after data standardization. Baseline characteristics were compared according to the group after clustering. Continuous and categorical variables are expressed as medians (interquartile range, IQR) and number (percentage), respectively. Rank-sum, Kruskal–Wallis and ANOVA F tests were employed for comparing continuous variables between groups. Fisher's exact or χ^2 tests were employed to compare categorical variables. The Kaplan–Meier method with log-rank testing was used in survival analysis. The Cox regression model was used to calculate HR and 95% CI. Two-tailed $p<0.05$ was

Table 1 Comparison of Baseline Characteristics Between Groups

	Cluster 1 (Noninflammatory)	Cluster 2 (Inflammatory)	*p*-value
Total	247	81	
Age, years	51 (42,57)	52 (46,58)	0.253
CRP	1.2 (0.4,3.5)	20.4 (7.8,47.3)	<0.001
Leukocyte count	6.0 (5.1,7.2)	8.9 (7.0,10.0)	<0.001
Neutrophil percentage	66.2 (61.0,72.0)	76.9 (72.6,81.3)	<0.001
Fibrinogen	3.4 (2.9,3.9)	5.0 (4.4,6.0)	<0.001
Platelet count	229 (181.5,269)	324 (270,405)	<0.001
Albumin	44.6 (42.7,46.5)	40.9 (38,43.7)	<0.001
Lymphocyte percentage	25.3 (19.9,30.4)	15.2 (11.7,19.7)	<0.001
CA125	111 (36.5,400.1)	697.1 (262.1,1785)	<0.001
BMI	22.9 (21.2,24.7)	23.4 (21,25.2)	0.757
GGT	14 (11,22)	19 (12,27)	0.012
ALT	18 (13,24.5)	14 (12,22)	0.028
AST	20 (17,24)	21 (17,25)	0.439
TBil	10.6 (7.8,14.2)	8.1 (6,11.5)	<0.001
DBil	4.1 (3.1,5.2)	3.5 (2.6,4.3)	0.002
IBil	6.6 (4.6,9.2)	4.7 (3.3,7.1)	<0.001
Creatinine	75.2 (66.2,81.2)	73.6 (64.5,80.8)	0.235
BUN	4.3 (3.5,5.2)	4.2 (3.2,5.3)	0.288
UA	247 (219.5,288.5)	244 (211,285)	0.348
HDL	1.3 (1.1,1.5)	1.1 (1,1.2)	<0.001
LDL	2.6 (2.2,3)	2.7 (2.3,3.1)	0.227
TG	1.2 (0.8,1.8)	1.3 (1.1,1.9)	0.099

Note: Data presented as medians (IQR).
Abbreviations: CA125, cancer antigen 125; BMI, body-mass index; GGT, γ-glutamyl transpeptidase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBil, total bilirubin; DBil, direct bilirubin; IBil, indirect bilirubin; BUN, blood urea nitrogen; UA, uric acid; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride.

considered statistically significant. All statistical analyses were performed using R version 3.5.1.

Results

Among the 645 patients collected between January 2014 and May 2019, 23 duplicates were excluded and another 229 patients excluded according to the aforementioned exclusion criteria. A total of 65 patients were not able to be clustered because of missing data of at least one of the included variables. Finally, 328 patients were included in the present study. Characteristics of patients included were shown in Table 1. *K*-mean clustering identified two clusters of patients (Figure 1A): 247 patients in cluster 1 and 81 in cluster 2. Average silhouette width was 0.16 (Figure 1B).

As shown in Table 2, cluster 2 featured a higher death/recurrence rate (*p*<0.001) and a higher proportion of advanced patients (*p*<0.001). Interestingly, cluster 2 presented higher levels of inflammation biomarkers, as shown in Table 1 and Figure 2. Median CRP levels were 20.4 (7.8–47.3) and 1.2 (0.4–3.5) in cluster 2 and cluster 1,

respectively (*p*<0.001). Median leukocyte counts were 8.9 (7.0–10.0) and 6.0 (5.1–7.2) in cluster 2 and cluster 1, respectively (*p*<0.001). Median neutrophil percentages were 76.9 (72.6–81.3) and 66.2 (61.0–72.0) in cluster 2 and cluster 1, respectively (*p*<0.001). Cluster 2 was also characterized by higher fibrinogen levels (*p*<0.001), higher platelet counts (*p*<0.001), lower albumin levels (*p*<0.001) and higher CA125 levels (*p*<0.001).

Concerning higher proportion of advanced tumors and higher levels of inflammation biomarkers in cluster 2, Table 3 shows associations between laboratory findings and FIGO stages. Table 3 indicates that CRP levels (*p*<0.001), neutrophil percentage (*p*<0.001), fibrinogen (*p*<0.001), platelet counts (*p*<0.001), and CA125 levels (*p*<0.001) ascended from stage I to stage IV, while albumin levels (*p*<0.001) and lymphocyte percentage (*p*<0.001) descended.

Survival Analysis

To further verify these results, survival analysis was carried out. Based on the elevated inflammation biomarkers,

A

B

Figure 1 Results of *kK*-mean clustering. (**A**) Results from cluster analysis; (**B**) silhouette information from clustering.

cluster 1 and cluster 2 were classed as noninflammatory and inflammatory subtypes of ovarian cancer, respectively. Median follow-up was 52 months, at which 21 (16.3%) patients in the noninflammatory group had died compared to 14 (29.8%) in the inflammatory group (*p*=0.076), as shown in Table 2. Cox regression analysis indicated an HR of 2.15 (95% CI 1.09–4.23, *p*=0.024 by log-rank test), as shown in Figure 3A. Death or recurrence was observed in 38 (29.5%) patients in the noninflammatory group and 25 (53.2%) in the inflammatory group (HR 2.32, 95% CI 1.40–3.85; *p*<0.001 by log-rank test) as shown in Figure 3B.

**Table 2** Comparison of Death Rate and Histopathological Characteristics Between Groups

	Cluster 1 (Noninflammatory)	Cluster 2 (Inflammatory)	*p*-value
Total	247	81	
Deaths (2014–2016)			0.076
Not observed	108 (83.7)	33 (70.2)	
Observed	21 (16.3)	14 (29.8)	
Deaths/recurrence (2014–2016)			0.006
Not observed	91 (70.5)	22 (46.8)	
Observed	38 (29.5)	25 (53.2)	
Grade			0.019
I	36 (20.1)	6 (8.5)	
II	14 (7.8)	2 (2.8)	
III	129 (72.1)	63 (88.7)	
Stage			<0.001
I	114 (46.2)	11 (13.6)	
II	33 (13.4)	9 (11.1)	
III	98 (39.7)	55 (67.9)	
IV	2 (0.8)	6 (7.4)	
Histological subtype			0.022
Serous	150 (60.7)	63 (77.8)	
Mucinous	32 (13)	2 (2.5)	
Endometrioid	21 (8.5)	4 (4.9)	
Clear cell	43 (17.4)	11 (13.6)	
Seromucinous	1 (0.4)	1 (1.2)	

Note: Data presented as n (%).

As one of the most important parameters of inflammation, CRP was selected to verify the association between inflammation and prognosis. CRP was dichotomized into two groups according to the median. The results in Table 4 indicate that CRP was an independent risk factor of overall survival (HR 3.79, 95% CI 1.54–9.33; *p*=0.001) and recurrence-free survival (HR 1.99; 95% CI 1.13–3.50; *p*=0.014). Subgroup analysis indicated that higher CRP was associated with poorer survival at both stage I–IIA (*p*=0.0094) and stage IIIB–IVB (*p*=0.026), as shown in Figure 4.

Discussion

Via *K*-mean clustering with preoperative laboratory results, we divided ovarian cancer patients into noninflammatory and inflammatory subtypes. The inflammatory subtype showed higher CRP, leukocyte counts, neutrophil percentage, fibrinogen, platelet counts, CA125, a higher proportion of patients in advanced stages, and lower levels of albumin. The inflammatory subtype was significantly associated with poor overall survival and recurrence-free survival.

Figure 2 Box plot of inflammatory biomarkers between two clusters. CRP, leukocyte count, neutrophil percentage, fibrinogen, platelet count, and CA125 were significantly higher in cluster 2.
Note: ***$p<0.001$.
Abbreviation: NS, not significant.

Elevated fibrinogen and platelet counts were observed along with elevated inflammatory markers in the inflammatory subtype. Inflammation is well recognized as a regulator of coagulation and fibrinolytic activity, which are context-dependent.[12] In inflammatory conditions, hemostatic balance may be shifted toward prothrombotic and antifibrinolytic states, with an increase in circulating serum factors.[12] Meanwhile, the proinflammatory effect of fibrinogen has been reported, either by stimulating macrophages to release inflammatory cytokine or leading the cascade of tissue repair and inflammatory responses.[13,14] In addition to hemostatic mechanisms, platelet-derived molecules have been found to mediate inflammation.[15—17] This evidence justifies the classification model in the present study, which

Table 3 Associations Between Laboratory Findings and FIGO Stages

|	Stage I	Stage II	Stage III	Stage IV	p-value
CRP*	1.1 (0.4,3.4)	1.5 (0.4,10.2)	3.7 (1.1,13.6)	32.6 (13.4,76.8)	<0.001
Leukocyte count*	6.4 (5.3,7.7)	6.2 (5,7.4)	6.7 (5.4,8.4)	6.7 (6.1,9.5)	0.204
Neutrophil percentage#	66.2 (10.4)	68.2 (8.7)	70.3 (8.2)	75.5 (5.1)	<0.001
Fibrinogen*	3.4 (2.9,3.9)	3.6 (3.2,4.4)	3.9 (3.2,4.8)	5 (4,6.5)	<0.001
Platelet count*	236 (193,280)	203 (170.5,268.2)	259 (205,319)	438 (321.2,455.8)	<0.001
Albumin*	44.9 (42.9,46.6)	43.7 (42.5,46.2)	43.3 (40.9,45.1)	37.4 (31.9,38.6)	<0.001
Lymphocyte percentage#	25.8 (9)	23.8 (7.6)	21.3 (7.1)	16.4 (4.3)	<0.001
CA125*	49 (21.4,111.2)	136.3 (49.9,399.3)	480.3 (186.2,1,179)	822.2 (428.6,1,668.5)	<0.001

Notes: *Data expressed as medians (IQR); #data expressed as means (SD).

emphasizes inflammation and interacting networks with various physiological processes.

The present study demonstrated that the ovarian cancer inflammatory subtype was linked to poor prognosis through cluster analysis. Similar results have been identified in previous studies. Neutrophil:lymphocyte ratio and platelet:lymphocyte ratio have been well investigated as inflammatory parameters closely related to ovarian cancer prognosis.[18—26] A meta-analysis verified the prognostic value of inflammatory markers in ovarian cancer patients.[27] With a novel method, *K*-mean cluster analysis, our study showed results consistent with previous research. Clustering is an unsupervised technique to classify a group of objects without prespecified labels into subgroups based on the similarity measure between objects.[28] In the present study, leukocyte count, neutrophil

percentage, and platelet count were higher in the inflammatory subgroup, which was related to poorer prognosis. In contrast, lymphocyte percentage was lower. Under the circumstances, both neutrophil:lymphocyte and platelet:lymphocyte ratios in the inflammatory subgroup were higher, and thus expected to be related to worse outcomes.

In our study, the inflammatory subgroup presented a higher proportion of advanced ovarian cancer patients. Inflammation and advanced stages are likely to be closely related. However, no causal relationship can be inferred from the results. Inflammation is well recognized as a hallmark of cancer.[29,30] Cross-talk between inflammation and cancer is quite complicated. Chronic inflammation predisposes tumor formation, while tumors elicit inflammation by reshaping the tumor microenvironment.[31] On one hand, inflammation takes part in tumor progression and metastasis.[31] Several signaling

Figure 3 Kaplan–Meier curves with log-rank tests. (**A**) Kaplan–Meier curves showed cluster 2 (inflammatory group) showed poorer overall survival; (**B**) cluster 2 (inflammatory group) was associated with poorer recurrence-free survival.

Table 4 Univariate and Multivariate Analyses for overall Survival and Recurrence-free Survival

	Univariate Analysis			Multivariate Analysis		
	Crude HR	95% CI	p-value	Adjusted HR*	95% CI	p-value
Overall survival						
CRP (high vs low)	5.84	2.42–14.09	<0.001	3.79	1.54–9.33	0.001
Stage	3.27	2.04–5.27	<0.001	3.02	1.80–5.07	<0.001
Type II	2.18	0.99–4.79	0.053	0.40	0.16–1.02	0.072
Age	1.05	1.02–1.09	0.001	1.04	1.00–1.08	0.037
Recurrence-free survival						
CRP (high vs low)	3.26	1.89–5.64	<0.001	1.99	1.13–3.50	0.014
Stage	3.44	2.40–4.93	<0.001	2.99	1.99–4.48	<0.001
Type II	3.49	1.82–6.70	<0.001	0.84	0.39–1.79	0.652
Age	1.04	1.02–1.07	<0.001	1.02	0.99–1.04	0.209

Note: *HRs adjusted by CRP, stage, type, and age.

pathways involved in the inflammatory response play important roles in ovarian cancer progression and metastasis. As a widely studied proinflammation cytokine, IL6 has been found to enhance expression of MMP9, which promoted tumor expansion and tumor-cell invasion in SKOV3 cells.[32] IL6 produced by M2 macrophages also stimulates the proliferation of SKOV3 cells via STAT3 activation.[33] In addition, it has been reported that IL6 *trans*-signaling on endothelial cells contributed to ovarian cancer progression by activating ERK.[34] These findings suggest the close relationship between inflammation and progression of ovarian cancer. On the other hand, tumors reshape the tumor microenvironment.[31] One pathway is that tumors promote inflammation in a hypoxia-dependent manner,[35,36] especially

in advanced cancers.[37] Compared with the normal nondiseased controls, ROS concentration has been reported at 96% higher in malignant ovarian tissue.[38] Although more studies are expected to elucidate the complexity, promising cancer treatment through inflammation manipulation is on the way.[39,40] The findings of the present study validated the impact of preoperative inflammation on ovarian cancer survival, which would provide more possibilities in ovarian cancer management.

There were major limitations of our study. Only some of the included patients were followed, and the follow-up might not have been long enough. This might have resulted in underestimated prognosis differences; however, according to the significantly different prognoses in the

Figure 4 Subgroup survival analysis. Kaplan–Meier curves showed higher CRP was associated with poorer overall survival in (**A**) stage I–IIA and (**B**) stage IIIB–IVB.

results, our follow-up duration might be sufficient to demonstrate prognosis differences. With further analysis of patient data and longer follow-up in future, it will be intriguing to explore more potential effects of our novel classification model in the clinical management of ovarian cancer. Another potential limitation is subjectivity in selection of variables to include and determination of the optimal number of clusters. Although the clustering was validated with survival analysis, the possibility still exists that other variables and other number of clusters might lead to a better classification paradigm.

Conclusion

Our cluster analysis identified two subtypes of ovarian cancer: noninflammatory and inflammatory. The inflammatory group featured higher CRP, leukocyte counts, neutrophil percentage, fibrinogen, platelet counts, CA125, and proportion of patients in advanced stages, with lower albumin levels and lymphocyte percentage. The inflammatory group was associated with poorer prognosis. The results of the present study should lead to further investigation into the cross-talk between inflammation and cancer.

Abbreviations

CA125, cancer antigen 125; CRP, C-reactive protein; BMI, body-mass index; GGT, γ-glutamyl transpeptidase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; TBil, total bilirubin; DBil, direct bilirubin; IBil, indirect bilirubin; BUN, blood urea nitrogen; UA, uric acid; HDL, high-density lipoprotein; LDL, low-density lipoprotein; TG, triglyceride; HR hazard ratio; CI, confidence interval; IQR, interquartile range; FIGO, International Federation of Gynecology and Obstetrics.

Author Contributions

All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Torre LA, Trabert B, DeSantis CE, et al. Ovarian cancer statistics, 2018. *CA Cancer J Clin*. 2018;68(4):284–296. doi:10.3322/caac.21456
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. 2018;68(6):394–424. doi:10.3322/caac.21492
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin*. 2020;70(1):7–30. doi:10.3322/caac.21590
4. Lheureux S, Gourley C, Vergote I, Oza AM. Epithelial ovarian cancer. *Lancet (London, England)*. 2019;393(10177):1240–1253. doi:10.1016/S0140-6736(18)32552-2
5. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. *Lancet (London, England)*. 2014;384(9951):1376–1388. doi:10.1016/S0140-6736(13)62146-7
6. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, et al. NCCN guidelines insights: ovarian cancer, version 1.2019. *J Natl Compreh Cancer Net*. 2019;17(8):896–909. doi:10.6004/jnccn.2019.0039
7. Kurman RJ, Shih IM. The Dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. *Am J Pathol*. 2016;186(4):733–747. doi:10.1016/j.ajpath.2015.11.011
8. Lisio MA, Fu L, Goyeneche A, Gao ZH, Telleria C. High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. *Int J Mo Sci*. 2019;20:4. doi:10.3390/ijms20040952
9. Zhang H, Liu T, Zhang Z, et al. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. *Cell*. 2016;166(3):755–765. doi:10.1016/j.cell.2016.05.069
10. Network TCGAR. Integrated genomic analyses of ovarian carcinoma. *Nature*. 2011;474(7353):609–615.
11. Colombo N, Sessa C, Du Bois A, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger. *Ann Oncol*. 2019;30(5):672–705. doi:10.1093/annonc/mdz062
12. Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. *Blood*. 2019;133(6):511–520. doi:10.1182/blood-2018-07-818211

13. Hsieh JY, Smith TD, Meli VS, Tran TN, Botvinick EL, Liu WF. Differential regulation of macrophage inflammatory activation by fibrin and fibrinogen. *Acta biomaterialia*. 2017;47:14–24. doi:10.1016/j.actbio.2016.09.024

14. Gobel K, Eichler S, Wiendl H, Chavakis T, Kleinschnitz C, Meuth SG. The coagulation factors fibrinogen, thrombin, and factor XII in inflammatory disorders-a systematic review. *Front Immunol*. 2018;9:1731. doi:10.3389/fimmu.2018.01731

15. Srivastava K, Cockburn IA, Swaim A, et al. Platelet factor 4 mediates inflammation in experimental cerebral malaria. *Cell Host Microbe*. 2008;4(2):179–187. doi:10.1016/j.chom.2008.07.003

16. Otterdal K, Smith C, Oie E, et al. Platelet-derived LIGHT induces inflammatory responses in endothelial cells and monocytes. *Blood*. 2006;108(3):928–935. doi:10.1182/blood-2005-09-010629

17. Mantovani A, Garlanda C. Platelet-macrophage partnership in innate immunity and inflammation. *Nature Immunol*. 2013;14(8):768–770. doi:10.1038/ni.2666

18. Ceran MU, Tasdemir U, Colak E, Gungor T. Can complete blood count inflammatory parameters in epithelial ovarian cancer contribute to prognosis? - a survival analysis. *J Ovarian Res*. 2019;12(1):16. doi:10.1186/s13048-019-0491-7

19. Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. *Clin Transl Oncol*. 2011;13(7):499–503. doi:10.1007/s12094-011-0687-9

20. Chen Y, Chen K, Xiao X, et al. Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. *BMC Cancer*. 2016;16:320. doi:10.1186/s12885-016-2352-8

21. Li Z, Hong N, Robertson M, Wang C, Jiang G. Preoperative red cell distribution width and neutrophil-to-lymphocyte ratio predict survival in patients with epithelial ovarian cancer. *Sci Rep*. 2017;7:43001. doi:10.1038/srep43001

22. Miao Y, Yan Q, Li S, Li B, Feng Y. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio are predictive of chemotherapeutic response and prognosis in epithelial ovarian cancer patients treated with platinum-based chemotherapy. *Cancer Biomark*. 2016;17(1):33–40. doi:10.3233/CBM-160614

23. Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, Srijaipracharoen S, Thavaramara T. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer. *J Gynecol Oncol*. 2012;23(4):265–273. doi:10.3802/jgo.2012.23.4.265

24. Wang Y, Liu P, Xu Y, et al. Preoperative neutrophil-to-lymphocyte ratio predicts response to first-line platinum-based chemotherapy and prognosis in serous ovarian cancer. *Cancer Chemother Pharmacol*. 2015;75(2):255–262. doi:10.1007/s00280-014-2622-6

25. Wang YQ, Jin C, Zheng HM, et al. A novel prognostic inflammation score predicts outcomes in patients with ovarian cancer. *Clinica Chimica Acta*. 2016;456:163–169. doi:10.1016/j.cca.2016.03.013

26. Williams KA, Labidi-Galy SI, Terry KL, et al. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. *Gynecol Oncol*. 2014;132(3):542–550. doi:10.1016/j.ygyno.2014.01.026

27. Zhu Y, Zhou S, Liu Y, Zhai L, Sun X. Prognostic value of systemic inflammatory markers in ovarian Cancer: a PRISMA-compliant meta-analysis and systematic review. *BMC Cancer*. 2018;18(1):443. doi:10.1186/s12885-018-4318-5

28. Karthik Ramasubramanian AS. *Machine Learning Using R*. 2017.

29. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646–674. doi:10.1016/j.cell.2011.02.013

30. Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. *Lancet Oncol*. 2014;15(11):e493–503. doi:10.1016/S1470-2045(14)70263-3

31. Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. *Immunity*. 2019;51(1):27–41. doi:10.1016/j.immuni.2019.06.025

32. Rabinovich A, Medina L, Piura B, Segal S, Huleihel M. Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of MMPs by autocrine IL-6. *Anticancer Res*. 2007;27(1a):267–272.

33. Takaishi K, Komohara Y, Tashiro H, et al. Involvement of M2-polarized macrophages in the ascites from advanced epithelial ovarian carcinoma in tumor progression via Stat3 activation. *Cancer Sci*. 2010;101(10):2128–2136. doi:10.1111/j.1349-7006.2010.01652.x

34. Lo CW, Chen MW, Hsiao M, et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. *Cancer Res*. 2011;71(2):424–434. doi:10.1158/0008-5472.CAN-10-1496

35. Balamurugan K. HIF-1 at the crossroads of hypoxia, inflammation, and cancer. *Int J Cancer*. 2016;138(5):1058–1066. doi:10.1002/ijc.29519

36. Triner D, Shah YM. Hypoxia-inducible factors: a central link between inflammation and cancer. *J Clin Invest*. 2016;126(10):3689–3698. doi:10.1172/JCI84430

37. Chan CY, Yuen VW, Wong CC. Hypoxia and the Metastatic Niche. *Advan Exp Med Biol*. 2019;1136:97–112.

38. Cohen S, Mehrabi S, Yao X, Millingen S, Aikhionbare FO. Reactive oxygen species and serous epithelial ovarian adenocarcinoma. *Cancer Res J*. 2016;4(6):106–114. doi:10.11648/j.crj.20160406.13

39. Ritter B, Greten FR. Modulating inflammation for cancer therapy. *J Exp Med*. 2019;216(6):1234–1243. doi:10.1084/jem.20181739

40. Shalapour S, Karin M. Pas de Deux: control of anti-tumor immunity by cancer-associated inflammation. *Immunity*. 2019;51(1):15–26. doi:10.1016/j.immuni.2019.06.021